Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370369 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Pharmacokinetics and Safety of Testosterone
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01370369 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT01370369, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label study of a single and repeated application of three dose levels of topical testosterone in hypogonadal males with morning serum testosterone concentrations \< 297 ng/dL.
Interventions
- DRUG Testosterone gel (FE 99903)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370369
The ClinicalTrials.gov registry entry for NCT01370369 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Testosterone gel (FE 99903) is the first listed.
NCT01370369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01370369 about?
NCT01370369 is a clinical study titled "Efficacy, Pharmacokinetics and Safety of Testosterone". This is an open-label study of a single and repeated application of three dose levels of topical testosterone in hypogonadal males with morning serum testosterone concentrations \< 297 ng/dL.
What is the current status of trial NCT01370369?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01370369?
The interventions under investigation include: Testosterone gel (FE 99903) (DRUG).
Who is sponsoring clinical trial NCT01370369?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.